Lee Tae Ho, Park Sungha, You Mi-Hyeon, Lim Ji-Hong, Min Sang-Hyun, Kim Byeong Mo
Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases (SIRIC), Yonsei University College of Medicine, Seoul, Korea.
J Neurochem. 2016 Mar;136(6):1232-1245. doi: 10.1111/jnc.13515. Epub 2016 Jan 21.
Alzheimer's disease (AD) is a chronic neurodegenerative disease and the risk of developing it increases with advancing age. In this study, we investigated the protective effects of saikosaponin C (SSc), one of the main bioactive components produced by the traditional Chinese herb, radix bupleuri, the root of Bupleurum falcatum, against AD in various neuronal models. Interestingly, we found that SSc has dual effects on AD by targeting amyloid beta (Aβ) and tau, two key proteins in AD. SSc significantly suppressed the release of both Aβ peptides 1-40 and 1-42 into cell culture supernatants, though it does not affect BACE1 activity and expression. SSc also inhibited abnormal tau phosphorylation at multiple AD-related residues. Moreover, SSc seems to have beneficial effects on cellular tau function; it accelerated nerve growth factor-mediated neurite outgrowth and increased the assembly of microtubules. In addition, SSc increased synaptic marker proteins such as synaptophysin and PSD-95. Considering its various biological activities, our results suggest that SSc might be a novel therapeutic tool for treating human AD and other neurodegenerative diseases. Tau and amyloid beta are two key features in Alzheimer's disease. Saikosaponin C, an active component of Bupleuri Radix, inhibits abnormal tau phosphorylation and amyloid beta production, thereby promoting synaptic integrity. Saikosaponin C also prevents amyloid beta-induced apoptosis in brain vascular endothelial cells. Therefore, Saikosaponin C may provide a new therapeutic strategy for treatment of neurodegenerative diseases, including Alzheimer's disease.
阿尔茨海默病(AD)是一种慢性神经退行性疾病,其发病风险随年龄增长而增加。在本研究中,我们调查了柴胡皂苷C(SSc)——传统中药柴胡(Bupleurum falcatum的根)产生的主要生物活性成分之一——在各种神经元模型中对AD的保护作用。有趣的是,我们发现SSc通过靶向AD中的两个关键蛋白淀粉样β蛋白(Aβ)和tau蛋白,对AD具有双重作用。SSc显著抑制Aβ肽1-40和1-42释放到细胞培养上清液中,尽管它不影响β-分泌酶1(BACE1)的活性和表达。SSc还抑制多个与AD相关残基处的tau蛋白异常磷酸化。此外,SSc似乎对细胞tau蛋白功能具有有益作用;它加速了神经生长因子介导的神经突生长,并增加了微管的组装。此外,SSc增加了突触标记蛋白,如突触素和突触后密度蛋白95(PSD-95)。考虑到其多种生物学活性,我们的结果表明SSc可能是治疗人类AD和其他神经退行性疾病的一种新型治疗工具。Tau蛋白和淀粉样β蛋白是阿尔茨海默病的两个关键特征。柴胡皂苷C是柴胡的一种活性成分,可抑制tau蛋白异常磷酸化和淀粉样β蛋白生成,从而促进突触完整性。柴胡皂苷C还可预防淀粉样β蛋白诱导的脑血管内皮细胞凋亡。因此,柴胡皂苷C可能为包括阿尔茨海默病在内的神经退行性疾病的治疗提供一种新的治疗策略。